Go to content
UR Home

Phase II Study of Cetuximab in Combination with Docetaxel in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck after Platinum-Containing Therapy: A Multicenter Study of the Arbeitsgemeinschaft Internistische Onkologie

URN to cite this document:
DOI to cite this document:
Knoedler, M. ; Gauler, T. C. ; Gruenwald, V. ; Matzdorff, A. ; Schroeder, M. ; Dietz, A. ; Jordan, W.-O. ; Arnold, B. ; Hennemann, Burkhard ; Keilholz, Ulrich
PDF - Published Version
Date of publication of this fulltext: 21 Oct 2019 09:12


Background: Cetuximab and docetaxel have single-agent activity in squamous cell carcinoma of the head and neck (SCCHN). The efficacy of their combination was evaluated in platinum-pretreated patients with recurrent and/or metastatic SCCHN. Patients and Methods: A total of 84 patients were treated with docetaxel 35 mg/m2 weekly for a maximum of 6 cycles and concomitant cetuximab 250 mg/m2 weekly ...


Owner only: item control page
  1. Homepage UR

University Library

Publication Server


Publishing: oa@ur.de
0941 943 -4239 or -69394

Dissertations: dissertationen@ur.de
0941 943 -3904

Research data: datahub@ur.de
0941 943 -5707

Contact persons